Inge C. van Gool
YOU?
Author Swipe
View article: Supplementary Figures from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
Supplementary Figures from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer Open
Supplementary Figures 1-3 with legends
View article: Supplementary Table 7 from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
Supplementary Table 7 from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer Open
Supplementary Table 7. Differential expression analysis of CD103+ vs CD103- CD8+ cytotoxic T cells
View article: Supplementary Figures from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
Supplementary Figures from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer Open
Supplementary Figures 1-3 with legends
View article: Data from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
Data from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer Open
The chemokine CXCL13 mediates recruitment of B cells to tumors and is essential for the formation of tertiary lymphoid structures (TLSs). TLSs are thought to support antitumor immunity and are associated with improved prognosis. However, i…
View article: Supplementary Tables 1-6, 8 from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
Supplementary Tables 1-6, 8 from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer Open
Supplementary Tables 1-6, 8
View article: Data from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
Data from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer Open
The chemokine CXCL13 mediates recruitment of B cells to tumors and is essential for the formation of tertiary lymphoid structures (TLSs). TLSs are thought to support antitumor immunity and are associated with improved prognosis. However, i…
View article: Supplementary Table 7 from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
Supplementary Table 7 from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer Open
Supplementary Table 7. Differential expression analysis of CD103+ vs CD103- CD8+ cytotoxic T cells
View article: Supplementary Tables 1-6, 8 from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer
Supplementary Tables 1-6, 8 from A Transcriptionally Distinct CXCL13<sup>+</sup>CD103<sup>+</sup>CD8<sup>+</sup> T-cell Population Is Associated with B-cell Recruitment and Neoantigen Load in Human Cancer Open
Supplementary Tables 1-6, 8
View article: Figure S1 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Figure S1 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues Open
Fluorescent In Situ Hybridization of Pole on metaphase spreads of Pole-mutant cell line
View article: Figure S3 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Figure S3 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues Open
Sensitivity to nucleoside analogs cytarabine and fludarabine in Pole S297F-mutant and Pole-wild-type cell lines
View article: Supplementary figure 2 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Supplementary figure 2 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer Open
Supplementary figure 2. CD3+ tumor infiltrate according to EC molecular subtype
View article: Figure S1 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Figure S1 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues Open
Fluorescent In Situ Hybridization of Pole on metaphase spreads of Pole-mutant cell line
View article: Table S3 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Table S3 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues Open
Oligonucleotide primer sequences to generate a template for homologous recombination for transfection
View article: Table S1 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Table S1 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues Open
POLE mutations identified in endometrial cancers in the observation arm of the PORTEC-1 trial
View article: Data from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Data from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer Open
Purpose: Recent studies have shown that 7% to 12% of endometrial cancers are ultramutated due to somatic mutation in the proofreading exonuclease domain of the DNA replicase POLE. Interestingly, these tumors have an excellent…
View article: Supplementary figure 1 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Supplementary figure 1 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer Open
Supplementary figure 1. Tumor infiltrating lymphocytes and Crohn's like reaction in POLE- mutant endometrioid endometrial cancers
View article: Supplementary table 1 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Supplementary table 1 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer Open
Supplementary table 1. Demographic and clinicopathological characteristics of cases by EC molecular subtype
View article: Figure S2 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Figure S2 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues Open
Spontaneous mutant frequency of Pole-mutant cell lines
View article: Figure S2 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Figure S2 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues Open
Spontaneous mutant frequency of Pole-mutant cell lines
View article: Supplementary figure 6 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Supplementary figure 6 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer Open
Supplementary figure 6. T cell exhaustion markers according to tumor CD8A expression and EC molecular subtype
View article: Table S5 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Table S5 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues Open
Sensitivity to adjuvant treatment strategies conferred by Pole proofreading domain mutations in a cell-based model
View article: Supplementary figure 4 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Supplementary figure 4 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer Open
Supplementary figure 4. CD20+ and FOXP3+ tumor infiltrate according to EC molecular subtype
View article: Supplementary table 2 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Supplementary table 2 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer Open
Supplementary table 2. Antigen presentation pathway mutations in TCGA POLE proofreading-mutant ECs
View article: Supplementary Methods from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Supplementary Methods from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues Open
Supplementary Methods
View article: Table S2 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Table S2 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues Open
Oligonucleotide guide RNA sequences to introduce Pole proofreading domain mutations through CRISPR-Cas9
View article: Table S6 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues
Table S6 from Adjuvant Treatment for <i>POLE</i> Proofreading Domain–Mutant Cancers: Sensitivity to Radiotherapy, Chemotherapy, and Nucleoside Analogues Open
Sensitivity to nucleoside analogs gemcitabine, cladribine and clofarabine conferred by Pole proofreading domain mutations in a cell-based model
View article: Supplementary figure 4 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Supplementary figure 4 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer Open
Supplementary figure 4. CD20+ and FOXP3+ tumor infiltrate according to EC molecular subtype
View article: Supplementary figure 1 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Supplementary figure 1 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer Open
Supplementary figure 1. Tumor infiltrating lymphocytes and Crohn's like reaction in POLE- mutant endometrioid endometrial cancers
View article: Supplementary figure 5 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Supplementary figure 5 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer Open
Supplementary figure 5. Expression of T cell markers and cytotoxic effectors by EC molecular subtype
View article: Supplementary table 1 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer
Supplementary table 1 from <i>POLE</i> Proofreading Mutations Elicit an Antitumor Immune Response in Endometrial Cancer Open
Supplementary table 1. Demographic and clinicopathological characteristics of cases by EC molecular subtype